FDA decisions loom for Kura’s ziftomenib and Bayer’s sevabertinib.
ApexOnco Front Page
Recent articles
The group scraps cobolimab, alongside MAbs against PVRIG and CD96.
AstraZeneca ended a tie-up with Asher, and then set off on its own.
The FDA has cleared GSK’s drug again, after a no from the advisory committee.
The company advances the IDRx-originated KIT inhibitor GSK6042981 into pivotal trials.
The G12C-selective elironrasib produces a 42% ORR in post-Lumakras/Krazati patients.
Redemption of sorts comes for IO Biotech, but there’s no respite for Summit.
But Perspective sinks again.
